API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. LSE /
  3. 0QZU.LSE

Vertex Pharmaceuticals Inc. (0QZU LSE) stock market data APIs

$468.015 2.75(0.6%) as of September 6, 2024
Price chart is built with Anychart

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc. Financial Data Overview

465.27
468.015
-
471.6001
465
342.0597-508.6699
0
0.4937
256 M
10 337 M
-13.9233
0.406
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '0QZU',
Type: 'Common Stock',
Name: 'Vertex Pharmaceuticals Inc.',
Exchange: 'LSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'UK',
CountryISO: 'GB',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: '',
Industry: '',
}

Vertex Pharmaceuticals Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 10 337 M
  • EBITDA 4 395 M
  • Earnings Per Share 9.475
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Vertex Pharmaceuticals Inc. Earnings via APIs

  • Latest Release 2024-08-01
  • EPS/Forecast NaN

Get Vertex Pharmaceuticals Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Vertex Pharmaceuticals Inc. latest news via APIs

Vertex Pharmaceuticals Incorporated (VRTX): Why Do Hedge Funds Recommend This Biotech Stock?

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds.In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

It has been about a month since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 1.6% in that time frame, underperforming the S&P 500. Will the recent negative trend...
Do you have any questions?
support@eodhistoricaldata.com